CD80 and neoplasm: Immune checkpoint therapies use monoclonal antibodies to enhance anti-tumor immunity by targeting pathways like CTLA-4, a T-cell receptor that inhibits activation by binding B7 proteins and boosts regulatory T-cell suppression [43].